Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-Related Macular Degeneration (AMD)
This study is ongoing, but not recruiting participants.
Study NCT00658619   Information provided by Allergan
First Received: April 11, 2008   Last Updated: April 16, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Macular Degeneration
Additional conditions recognized in this trial
Atrophy
More general conditions related to this trial
Eye Diseases
Pathological Conditions, Anatomical
Retinal Degeneration
Retinal Diseases
Interventions listed in this trial
Brimonidine Tartrate Implant
Sham
Additional drug interventions recognized in this trial
Brimonidine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-Agonists
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Allergan


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services